Advertisement

Search Results

Advertisement



Your search for can matches 13380 pages

Showing 1001 - 1050


leukemia
lymphoma
hematologic malignancies

Nemtabrutinib May Provide Benefit in Patients With Relapsed Hematologic Malignancies

The BTK inhibitor nemtabrutinib may offer a new treatment option for patients with relapsed hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, according to a recent study published by Woyach et al in Cancer Discovery. Background Hematologic malignancies are...

lung cancer
issues in oncology

Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates

Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...

issues in oncology

Can High BMI in Youth Affect Cancer Risk Later On?

Men with overweight or obesity at age 18 years may have a higher risk of 17 different cancers later in life, according to recent research from the University of Gothenburg. The findings also describe how the youth obesity epidemic is expected to affect cancer incidence over the next 30 years. In...

sarcoma
issues in oncology

Machine-Learning Model May Accurately Calculate Chemotherapy Success in Patients With Osteosarcoma

Researchers have developed and trained a new machine learning model to calculate percent necrosis in patients with osteosarcoma, according to a novel study published by LiBrizzi et al in the Journal of Orthopaedic Research. Background A postchemotherapy percent necrosis calculation often helps...

lymphoma
issues in oncology

Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL

Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...

colorectal cancer
issues in oncology

Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients

Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...

solid tumors
issues in oncology

Novel Blood Test May Offer Early Cancer Detection

Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...

lung cancer
cns cancers
issues in oncology

Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases

Researchers have explored the impact of immune checkpoint inhibition and single-fraction stereotactic radiosurgery on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases, according to a novel study published by Lehrer et al in the Journal of Neuro-Oncology. Study ...

leukemia
issues in oncology
global cancer care

Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL

Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...

lung cancer
skin cancer
cost of care

Patients With Newly Diagnosed NSCLC or Melanoma May Receive Limited Documentation of Treatment Cost Discussions

Investigators have uncovered that only about 25% of patients newly diagnosed with advanced cancer have documented physician discussions about the costs of care, which may make it more difficult to identify patient needs and track the outcomes of referrals for assistance, according to new findings...

cost of care
survivorship

Role of Crowdfunding Campaigns in Covering Medical Expenses for Cancer Survivors

Investigators have discovered that cancer survivors in the United States may be increasingly utilizing crowdfunding campaigns like GoFundMe to help cover the costs of medical and other basic household expenses, according to new findings presented by Zheng et al and Yu et al at the 2023 ASCO Quality ...

Expert Point of View: Rohann J.M. Correa, MD, PhD

Abstract discussant Rohann J.M. Correa, MD, PhD, a radiation oncologist at London Health Sciences Centre and Assistant Professor at Western University, Canada, shared his insights on this landmark clinical trial for the treatment of kidney cancers. “FASTRACK II represents an important milestone,...

kidney cancer

Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma

Although surgery remains the standard of care for primary renal cell carcinoma, a novel, noninvasive approach has yielded positive results that could pave the way for future treatment strategies, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual...

prostate cancer

PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer

Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...

thyroid cancer
issues in oncology

PFAS Exposure May Increase Risk of Thyroid Cancer

Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...

solid tumors
issues in oncology
immunotherapy

Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy

Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...

head and neck cancer
supportive care

Yoga-Based Supportive Care May Prevent Treatment-Related Complications in Patients With Head and Neck Cancer

Yoga-based supportive care may help alleviate the negative side effects of radiation treatment, decrease the use of feeding tube placements, and reduce emergency department visits in patients with head and neck cancer, especially when family caregivers participate, according to new findings...

supportive care
symptom management
solid tumors

Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care

Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....

issues in oncology

Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities

It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...

covid-19

Annual Report to the Nation on COVID-19’s Impact on Cancer Diagnosis Finds Sharp Declines in New Diagnoses of Six Major Cancers

Findings from the Annual Report to theNation on the Status of Cancer, Part 2: Early Assessment of the COVID-19 Pandemic’s Impact on Cancer Diagnosis show new diagnoses of six major cancer types in the United States fell sharply between March and May 2020, coinciding with the beginning of the...

cardio-oncology

Diagnosis of Cardiovascular Disease and Risk of Subsequent Incident Cancer Diagnosis

In a retrospective cohort study reported in JACC: CardioOncology, Caitlin F. Bell, MD, of the Division of Cardiovascular Medicine, Stanford University School of Medicine, and colleagues found that persons with a diagnosis of cardiovascular disease (CVD) were more likely to have a subsequent...

Expert Point of View: Matthew Hatton, MBChB, MSc, FRCP, FRCR and Charles Simone, MD

Invited discussant Matthew Hatton, MBChB, MSc, FRCP, FRCR, a consultant and Honorary Professor in Clinical Oncology at Weston Park Cancer Center, Sheffield, UK, pointed out that the original analysis of RTOG 0617 was disappointing and failed to find evidence that intensity-modulated radiation...

Expert Point of View: Helena Linardou, MD, PhD

Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, was invited as the discussant of the studies on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Preliminary Data Dr. Linardou...

hematologic malignancies
issues in oncology

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

Gender diversity, equity, and inclusion (DEI) in medicine has long been acknowledged as more than “the right thing to do,” with clear evidence of benefits in innovation, collaboration, and workplace culture.1 Yet the data continue to showcase challenges in achieving these goals despite women...

leukemia

Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present

I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...

global cancer care

From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...

breast cancer
issues in oncology

Patient Education Materials on Breast Cancer May Be Difficult to Access

Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...

breast cancer
thyroid cancer
pancreatic cancer
issues in oncology

AI-Based Calculator May Accurately Predict Long-Term Cancer Survival

Researchers have developed a novel artificial intelligence (AI)-based Cancer Survival Calculator for estimating long-term survival in patients with newly diagnosed cancer, according to new findings presented by Janczewski et al at the American College of Surgeons (ACS) Clinical Congress 2023....

breast cancer
survivorship

Novel Strategies for Eliminating Dormant Tumor Cells in Breast Cancer Survivors

Researchers have discovered that it may be possible to detect and treat dormant tumor cells in breast cancer survivors, according to new findings presented by DeMichele et al at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract 244MO). The results may have offered a...

skin cancer
immunotherapy

Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...

gynecologic cancers
issues in oncology

Induction Chemotherapy and Subsequent Chemoradiation May Improve Survival and Recurrence Rates in Patients With Cervical Cancer

Researchers have found that a short course of induction chemotherapy prior to chemoradiation may be effective at reducing the rate of relapse and mortality among patients with locally advanced cervical cancer, according to new preliminary findings presented by McCormack et al at the European...

skin cancer

ESMO 2023: New Data in Skin Cancers

At the European Society for Medical Oncology (ESMO) Congress 2023, new findings are being presented in cutaneous squamous cell carcinoma, late-stage melanoma, and refractory melanoma brain metastases. Presurgical Immunotherapy in Advanced Operable Cutaneous Squamous Cell Carcinoma Patients with...

gynecologic cancers

PARP inhibitor Plus Immunotherapy Added to Chemotherapy Lowers Risk of Disease Progression in Patients With Advanced Endometrial Cancer

Immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in the...

kidney cancer

EVEREST Trial: Adjuvant Everolimus for High-Risk Clear Cell Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectomy who received adjuvant everolimus had a statistically significant improvement in recurrence-free survival compared to patients who...

lung cancer
immunotherapy

Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC

Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...

multiple myeloma
issues in oncology

Is Idecabtagene Vicleucel Effective in Patients With Multiple Myeloma, Regardless of Race?

The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel may offer an overall survival benefit in patients with multiple myeloma, regardless of their race or ethnicity, according to a novel study published by Peres et al in Blood Advances. Background Multiple myeloma—a cancer of...

solid tumors
issues in oncology

Patients and Survivors of Cancer May Be Impacted by U.S. Drug Shortages

The drug shortage crisis in the United States may continue to impact the care of 10% of patients and survivors of cancer, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Findings In the new survey, researchers asked 1,222 patients and survivors of...

sarcoma

Efficacy of Radiotherapy in Rhabdomyosarcoma

In an analysis of data from two clinical trials and a soft-tissue sarcoma registry reported in the Journal of Clinical Oncology, Koscielniak et al identified which patients aged ≤ 21 years with localized rhabdomyosarcoma appeared to derive benefit from radiation therapy. Study Details The study...

issues in oncology

Blood-Based Testing for Multicancer Early Detection

In a prospective cohort study (PATHFINDER) reported in The Lancet, Deb Schrag, MD, MPH, FASCO, and colleagues evaluated the performance of blood-based testing for multicancer early detection in adults without signs or symptoms of cancer.  As stated by the investigators, “Multicancer early detection ...

solid tumors
genomics/genetics

Almost Half of Oncology Drugs Approved Since 1998 Have Been Precision Therapies, New Study Finds

Among the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% of them were precision therapies, according to a recent study published by Suehnholz et al in Cancer Discovery. Background Precision oncology therapies often require...

prostate cancer
issues in oncology

MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer

Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...

breast cancer

Air Pollution and Breast Cancer Risk: Residential and Workplace Exposure

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of a study looking at the effects of both residential and workplace exposure to air pollution on breast cancer risk ...

colorectal cancer
issues in oncology

Gut Microbiome Variations and Colorectal Cancer Risk

Researchers have identified significant variations in the gut microbiome of patients with precancerous colorectal lesions, suggesting a potential correlation between gut bacteria and the onset of precancerous lesions and colorectal cancer, according to new findings presented by Gacesa et al at...

issues in oncology
genomics/genetics

The Future of AI in Cancer Care

New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Background Researchers have long investigated the potential of ...

breast cancer

Breast Cancer 2022–2023 Almanac

The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...

Expert Point of View: Virginia Kaklamani, MD

Breast medical oncologist Virginia Kaklamani, MD, Professor of Medicine, UT Health San Antonio, MD Anderson Cancer Center, believes the results of the POSITIVE trial will help patients with breast cancer make decisions. “The trial is important because it helps us give advice to younger patients,”...

breast cancer

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...

Expert Point of View: Polly Niravath, MD and Virginia Kaklamani, MD

The invited discussant of the SOFT analysis was Polly Niravath, MD, Associate Professor and Director of the Cancer Survivorship Program at Houston Methodist Hospital in Texas. She noted that the study evaluated the use of the Breast Cancer Index (BCI) as a prognostic tool in early hormone...

breast cancer

SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression

In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...

breast cancer
immunotherapy

Expert Point of View: Neelima Vidula, MD

Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...

Advertisement

Advertisement




Advertisement